This observational study will evaluate the glucocorticoid sparing effect after 12 months of treatment with RoActemra/Actemra (tocilizumab) in patients with rheumatoid arthritis. Data will be collected for 12 months after the initiation of treatment with RoActemra/Actemra from patients who had been on treatment with >5 mg prednisone or equivalent for at least 3 months .
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01392001?cond=%22Arthritis%22&lup_s=10/31/2013&lup_d=30
